Dr. Mell on Toxicities Associated With GL-ONC1 for Head and Neck Cancer

Video

Loren K. Mell, MD, chief, Head and Neck Malignancy Service, associate professor, University of California, San Diego, discusses toxicities associated with GL-ONC1 for the treatment of patients with head and neck cancer.

Loren K. Mell, MD, chief, Head and Neck Malignancy Service, associate professor, University of California, San Diego, discusses toxicities associated with GL-ONC1 for the treatment of patients with head and neck cancer.

GL-ONC1 is an attenuated vaccinia virus that demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy for patients with locoregionally advanced head and neck cancer, as seen in a phase I study.

GL-ONC1 was found to be a well-tolerated agent in this study. The most common adverse events observed were low-grade, short-term rash and flu-like symptoms. Based on the foundation of GL-ONC1, its safety profile was expected. However, researchers were unsure if the agent would be just as tolerable when combined with chemotherapy.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,